Details for New Drug Application (NDA): 209347
✉ Email this page to a colleague
NDA 209347 describes GANZYK-RTU, which is a drug marketed by Exela Pharma and is included in one NDA. There is one patent protecting this drug. Additional details are available on the GANZYK-RTU profile page.
The generic ingredient in GANZYK-RTU is ganciclovir. There are twenty-seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ganciclovir profile page.
The generic ingredient in GANZYK-RTU is ganciclovir. There are twenty-seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ganciclovir profile page.
Summary for 209347
| Tradename: | GANZYK-RTU |
| Applicant: | Exela Pharma |
| Ingredient: | ganciclovir |
| Patents: | 1 |
Medical Subject Heading (MeSH) Categories for 209347
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SOLUTION;INTRAVENOUS | Strength | 500MG/250ML (2MG/ML) | ||||
| Approval Date: | Feb 17, 2017 | TE: | RLD: | Yes | |||||
| Patent: | 9,486,530 | Patent Expiration: | Sep 2, 2034 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Complete Access Available with Subscription
